Objective: We aimed to study the success and false negative rate of sentinel lymph node biopsy(SLNB) in different clinical stages breast cancer patients being carried out with neoadjuvant chemotherapy(NAC), and the clinical significance of SLNB, we conducting this trial. Methods: One hunderd and thirty-seven cases were enrolled in this clinical research from March 2003 to March 2007. All of the patients' sentinel lymph nodes were detected with99mTc-Dx and methylene blue. There were 61 patients with stage T1–2 N0 M0 carried SLNB without NAC(group A), 76 cases were carried out NAC 3–4 cycles before SLNB, including 39 T2–4 N0–1 M0 cases(group B) and 27 T2–4 N2–3 M0 cases(group C). The success and false negative rate of SLNB were analysed with chi-square test. Results: In group A, the successful and false negative rate of SLNB were 92.31%(36/39), 8.57%(3/35), and in group B and C were 92.31%(36/39), 8.57%(3/35) and 74.07 %(20/27), 18.52 %(5/27), respectively. The successful rate of group C decreased and false negative rate increased significantly compared with group A and B(P 0.05). Conclusion: The SLNB can accurately predict lymph node status of axillary lymph node in N0–1 stage patients with NAC, but in N2–3 stage patients the success rate decreased and false rate increased negative significantly.
展开▼
